

## International Conference “Sustainability of the EU Pharma and Healthcare Market”

30 March 2026, Kraków, Jagiellonian University, Gołębia 24 street, 2<sup>nd</sup> floor, Aula

Time	Topic	Speaker
8.45 -9.30	Registration and Coffee	
09:30-9.50	Welcome  Welcome	<b>Prof Justyna Ożegalska-Trybalska</b> , Director, Intellectual Property Law Chair, Jagiellonian University  <b>Dr Żaneta Zemła-Pacud</b> , Deputy President, The Polish Patent Office
9.50 – 10.15	<b>Keynote speech:</b> <i>Strengthening Europe’s Health Innovation in the New Realities: Competitiveness, Access, and Health Sovereignty by Design</i>	<b>Prof Timo Minssen</b> , Director, the Centre for Advanced Studies in Bioscience Innovation Law, University of Copenhagen
10.15-12.00	<b>Panel I: Rethinking Legal, Regulatory and Policy Tools to Ensure the Sustainability of the EU’s Pharma and Healthcare Market</b>	<b>Chair: Prof Kathy Liddell</b> , Director, Centre for Law, Medicine and Life Sciences, University of Cambridge
	<i>EU IP Policy Developments for the Pharma Sector</i>	<b>Vytenis Semeta</b> , IP Unit, DG GROW, European Commission
	<i>Reshaping Medical Innovation Ecosystems: IP and Regulatory Hurdles and Opportunities</i>	<b>Prof Frantzeska Papadopoulou</b> , Stockholm University
	<i>How Can innovation Policy Address ‘Market failures’ in the Development of Novel Medicines?</i>	<b>Prof Michael Hopkins</b> , University of Sussex Business School
	<i>Intellectual Property Rights and the Sustainability of Health Systems - Towards Broader Policy Shift?</i>	<b>Prof Maria Vazquez</b> , University of San Andres in Buenos Aires
	<i>The Barrier Around Antibody Inventions at the European Patent Office</i>	<b>Tamaris Bucher</b> , Principal Patent Attorney, Novartis
12:00-13:30	<b>Panel II Promoting Secure and Affordable Access to Medicines</b>	<b>Chair: Dr Dariusz Kasprzycki</b> , Jagiellonian University
	<i>Revision of existing legislation, including the EU Cross-border Healthcare Directive and the EU Blood, Tissues and Cells Directive</i>	<b>Dr Andrzej Ryś</b> , Polish Medical Research Agency

	<i>Unproven cell interventions: exploitation of European Union law on advanced therapy medicinal products</i>	<b>Prof Marlena Pecyna</b> , Jagiellonian University
	<i>ATMPs by Exemption: Exception or Pathway?</i>	<b>Dr Gabriela Lenarczyk</b> , the Centre for Advanced Studies in Bioscience Innovation Law, University of Copenhagen
	<i>Promoting Access to Orphan Drugs</i>	<b>Dr Jin Ding</b> , University of Sheffield
<b>13.30-14:15</b>	<b>Lunch</b>	
<b>14.15-15.45</b>	<b>Panel III: <i>Balancing and Enforcing IP Rights in the Pharma Sector</i></b>	<b>Chair: Prof Christoph Rademacher</b> , Waseda University in Tokyo
	<i>Enforcement of Regulatory Exclusivities</i>	<b>Dr Żaneta Zemła-Pacud</b> , Associate Professor, Polish Academy of Science
	<i>Interim relief at the UPC and other Leading European Jurisdictions</i>	<b>Prof Rafał Sikorski</b> , Adam Mickiewicz University in Poznań
	<i>Balancing Tools in Pharma Patent Disputes</i>	<b>Justyna Rasiewicz</b> , Partner ROA, Infarma
	<i>Establishing Guardrails for General-Purpose Technologies</i>	<b>Prof Franziska Bächler</b> , Center for Life Sciences Law at the University of Basel
<b>15:45-16.15</b>	<b>Coffee break</b>	
<b>16.15-17.30</b>	<b>Panel IV: <i>Enhancing Crisis Preparedness Response Mechanisms in the EU</i></b>	<b>Chair: Prof Justyna Ożegalska-Trybalska</b> , Intellectual Property Law Chair, Jagiellonian University
	<i>Health Technology Assessment as a Tool for Enhancing Health Crisis Preparedness</i>	<b>Dr Roman Topór-Mądry</b> , Director, Interdisciplinary Health Data Centre, Collegium Medicum, Jagiellonian University
	<i>Production and Supply of Active Substances for Critical Medicines in Europe</i>	<b>Grzegorz Rychwalski</b> , The Association of the Generic Producers
	<i>Improved Drug Security and Accessibility: IP and Regulatory Pathways for the EU Health System Resilience and Crisis Preparedness</i>	<b>Dr Laura Valtere</b> , Centre for Advanced Studies in Bioscience Innovation Law, University of Copenhagen
	<i>From Legacy to Leadership: Rebuilding Ukraine's Pharmaceutical Industry in EU Partnership</i>	<b>Dr Peter R. Slowinski</b> , Max Planck Institute for Innovation and Competition in Munich
<b>17.30</b>	<b>Closing remarks</b>	
<b>18.00 -20.30</b>	<b>Reception, Larisch Palace, Bracka 12 street, Representative Hall</b>	



*The conference has been supported by a grant from the Faculty of Law and Administration under the Strategic Programme Excellence Initiative at Jagiellonian University*



*The conference organised under the honorary patronage of the Patent Office of the Republic of Poland*